🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“Reflection, Learning and Action” this is my train of thought while dealing with MM.

Thank you Myeloma Canada for the opportunity share my story while attending your SGLS.

This has worked really well for patients that I’ve known on it!

Belantamab Mafodotin-blmf No Longer Available for Relapsed/Refractory Myeloma in US cancernetwork.com/view/belantama… via CancerNetwork® Bela remains available for pts currently receiving and responding to it. Your doctor and GSK can help you. @MyelomaTeacher - Cindy Chmielewski

Dr Costa Luciano J Costa shows one reason it's difficult accruing AA pts into #myeloma Clinical Trials. #ASH22 #IMFASH22 #IMFsupport

Is it time to RedirecTT myeloma? Combining Teclistamab and Talquetamab is feasible but CRS and infections still common as with monotherapies. Efficacy is very impressive with ORR over 90%!! #ASCO23 #MMSM #MedIQ23ASCO

Click the link below to view the first four episodes of the “MYE Journey” podcast. Myself along with Cristina Gasparetto have a candid conversation about our patient/hematologist relationship. dukecancerinstitute.org/news/watch-onc… #multiplemyeloma #mmsm

FDA Greenlights Erlanatamab for Relapsed or Refractory Multiple Myeloma targetedonc.com/view/fda-green… via Targeted Oncology Another FDA approval for a bispecific treatment for myeloma.

I am looking forward to the conversation as well. Join us on fb 08/31 @ 7

"The Interconnectednes of Dietery Habits With QOL and Outcome in MM" Dr Urvi Shah thank you for presenting at the 24th Annual International Myeloma Foundation Support Group Leaders Summit the leaders loved your presentation. #mmsm

Always an incredible time at the IMF Support Group Leaders Summit! I simply love these people and their commitment…Yelak Biru Robin Tuohy Thomas Goode International Myeloma Foundation

Thank you Myeloma Canada for allowing me the opportunity to attend #Healthematters #mmsm #multiplemyeloma #cancerawareness

In 2023, our M-Power initiative achieved remarkable milestones, fostering diversity and equity in myeloma care. Together, we're shaping a future where every voice is heard and every patient receives the support they deserve. Joseph Mikhael 🌍💪 #MPower2023 #DiversityInHealthcare 🌟

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma cancernetwork.com/view/belantama… via @CancerNetwork® This is great news for #myeloma pts. I predict DREAMM8 will show even better results for Blenrep. FDA please approve this ADC.

High-risk multiple myeloma is a subgroup of people with multiple myeloma that experience poor disease outcomes. Learn what treatment options are available for high-risk multiple myeloma. patientpower.info/multiple-myelo…